# The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany

> **NCT03205722** · — · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT03205722
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-01-05
- **Primary completion:** 2018-07-30
- **Final completion:** 2018-07-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2018-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03205722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03205722, "The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03205722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*